Unlike the U.S. market, the U.K. market has never been very fond of technology stocks, including biotechnology companies. Their valuations—and the levels of interest they attract—are usually low.
That’s why recently a British biotechnology company with expertise in the emerging and increasingly profitable field of biological analysis delisted in Britain and moved its sole listing to the Nasdaq. It has had a secondary listing here since October 2020.
This post originally appeared at Investors Alley.